(Q33893669)

29 July 2017

1 reference

title

Risk factors for and management of cognitive dysfunction in multiple sclerosis (English)

1 reference

29 July 2017

0 references

cognitive dysfunction

1 reference

2

Robert Zivadinov

1 reference

29 July 2017

Ralph H B Benedict

1

1 reference

PubMed ID

21556031

29 July 2017

language of work or name

English

0 references

publication date

10 May 2011

1 reference

29 July 2017

Nature Reviews Neurology

1 reference

29 July 2017

7

1 reference

29 July 2017

332-342

1 reference

29 July 2017

6

1 reference

https://scigraph.springernature.com/pub.10.1038/nrneurol.2011.61

29 July 2017

0 references

cites work

The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Multiple sclerosis-related cognitive changes: a review of cross-sectional and longitudinal studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Minimal neuropsychological assessment of MS patients: a consensus approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Cognitive impairment in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Interpreting patient/informant discrepancies of reported cognitive symptoms in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Is speed of processing or working memory the primary information processing deficit in multiple sclerosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Information processing efficiency in patients with multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

On the nature of memory disturbance in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Acquisition and storage deficits in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

The relationship between cognitive deficits and everyday functional activities in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Predicting quality of life in multiple sclerosis: accounting for physical disability, fatigue, cognition, mood disorder, personality, and behavior change.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Evaluating storage, retention, and retrieval in disordered memory and learning

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Paced auditory serial-addition task: a measure of recovery from concussion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Cognitive impairment and decline in different MS subtypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Cognitive performance and MR markers of cerebral injury in cognitively impaired MS patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Reliability, practice effects, and change indices for Rao's Brief Repeatable Battery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Guidelines for neuropsychological research in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Sensitivity of conventional memory tests in multiple sclerosis: comparing the Rao Brief Repeatable Neuropsychological Battery and the Minimal Assessment of Cognitive Function in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Influence of recruitment and participation bias in neuropsychological research among MS patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Validity of the Wisconsin Card Sorting and Delis-Kaplan Executive Function System (DKEFS) Sorting Tests in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

A longitudinal study of brain atrophy in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Cognitive function in primary progressive and transitional progressive multiple sclerosis: a controlled study with MRI correlates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Cognitive impairment as marker of diffuse brain abnormalities in early relapsing remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Differences in cognitive impairment of relapsing remitting, secondary, and primary progressive MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Cognitive dysfunction in patients with relapsing-remitting multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

The utility of regression-based norms in interpreting the minimal assessment of cognitive function in multiple sclerosis (MACFIMS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Screening for cognitive impairment in multiple sclerosis using the Symbol digit Modalities Test.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Neocortical atrophy, third ventricular width, and cognitive dysfunction in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

A semiautomated measure of whole-brain atrophy in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Memory impairment in multiple sclerosis: correlation with deep grey matter and mesial temporal atrophy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Independent contributions of cortical gray matter atrophy and ventricle enlargement for predicting neuropsychological impairment in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Diffusion-weighted imaging predicts cognitive impairment in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Prediction of neuropsychological impairment in multiple sclerosis: comparison of conventional magnetic resonance imaging measures of atrophy and lesion burden.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Psychometrics and normative data for the Multiple Sclerosis Functional Composite: replacing the PASAT with the Symbol Digit Modalities Test

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

PASAT in detecting cognitive impairment in relapsing-remitting MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Repeated assessment of neuropsychological deficits in multiple sclerosis using the Symbol Digit Modalities Test and the MS Neuropsychological Screening Questionnaire.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Evaluation of the symbol digit modalities test (SDMT) and MS neuropsychological screening questionnaire (MSNQ) in natalizumab-treated MS patients over 48 weeks.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Predicting loss of employment over three years in multiple sclerosis: clinically meaningful cognitive decline

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Cognitive aging in patients with multiple sclerosis: a cross-sectional analysis of speeded processing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Cognitive dysfunction in early-onset multiple sclerosis: a reappraisal after 10 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Cognitive and psychosocial features in childhood and juvenile MS: two-year follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Sex differences in cognitive impairment in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Does multiple sclerosis-associated disability differ between races?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Cognitive dysfunction in patients with clinically isolated syndromes or newly diagnosed multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Brain MRI correlates of cognitive impairment in primary and secondary progressive multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Influence of clinical variables on neuropsychological performance in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Gray matter atrophy in multiple sclerosis: a longitudinal study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Smoking is a risk factor for multiple sclerosis: a metanalysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Smoking is associated with progressive disease course and increased progression in clinical disability in a prospective cohort of people with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Multiple sclerosis with predominant, severe cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Multiple sclerosis and cannabis: a cognitive and psychiatric study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Neuropsychological deficits in long-term frequent cannabis users.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Personality and medical illness burden among older adults in primary care.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

The NEO-FFI in Multiple Sclerosis: internal consistency, factorial validity, and correspondence between self and informant reports

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Cortical atrophy and personality in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Apolipoprotein E: far more than a lipid transport protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Accelerated evolution of brain atrophy and "black holes" in MS patients with APOE-epsilon 4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Influence of apolipoprotein E epsilon4 genotype on brain tissue integrity in relapsing-remitting multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

An APOA1 promoter polymorphism is associated with cognitive performance in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Cognitive impairment in patients with multiple sclerosis: association with the APOE gene and promoter polymorphisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

APOE epsilon4 and the cognitive genetics of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Apolipoprotein genotype does not influence MS severity, cognition, or brain atrophy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Multiple sclerosis susceptibility-associated SNPs do not influence disease severity measures in a cohort of Australian MS patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Preservation of gray matter volume in multiple sclerosis patients with the Met allele of the rs6265 (Val66Met) SNP of brain-derived neurotrophic factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

The rs2030324 SNP of brain-derived neurotrophic factor (BDNF) is associated with visual cognitive processing in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

The effects of BDNF Val66Met polymorphism on brain function in controls and patients with multiple sclerosis: an imaging genetic study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

The genetics of multiple sclerosis: SNPs to pathways to pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

The contribution of magnetic resonance imaging to the diagnosis of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Fluid-attenuated inversion recovery magnetic resonance imaging detects cortical and juxtacortical multiple sclerosis lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Accumulation of hypointense lesions ("black holes") on T1 spin-echo MRI correlates with disease progression in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Role of MRI in multiple sclerosis I: inflammation and lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Correlation of magnetic resonance imaging with neuropsychological testing in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Intracortical lesions in multiple sclerosis: improved detection with 3D double inversion-recovery MR imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

T1 cortical hypointensities and their association with cognitive disability in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Accumulation of cortical lesions in MS: relation with cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

The pathological evolution of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Axonal transection in the lesions of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Axonal pathology in multiple sclerosis: relationship to neurologic disability

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Correlation of volumetric magnetization transfer imaging with clinical data in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Changes in the normal appearing brain tissue and cognitive impairment in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Cognitive dysfunction in patients with mildly disabling relapsing-remitting multiple sclerosis: an exploratory study with diffusion tensor MR imaging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Serial neuropsychological assessment and magnetic resonance imaging analysis in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Hippocampal atrophy in relapsing-remitting and primary progressive MS: a comparative study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Regional hippocampal atrophy in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Structural brain abnormalities in multiple sclerosis patients with major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Influence of education and occupation on the incidence of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Cognitive reserve and Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

fMRI evidence of brain reorganization during attention and memory tasks in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Cerebral activation patterns during working memory performance in multiple sclerosis using FMRI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Cognitive reserve moderates the negative effect of brain atrophy on cognitive efficiency in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Premorbid cognitive leisure independently contributes to cognitive reserve in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Intellectual enrichment is linked to cerebral efficiency in multiple sclerosis: functional magnetic resonance imaging evidence for cognitive reserve.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Evidenced-based cognitive rehabilitation for persons with multiple sclerosis: a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Treating learning impairments improves memory performance in multiple sclerosis: a randomized clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Membranes, myelin, and the pathophysiology of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

The effects of 4-aminopyridine in multiple sclerosis patients: results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Fatigue in progressive multiple sclerosis: results of a randomized, double-blind, placebo-controlled, crossover trial of oral 4-aminopyridine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

The effects of amantadine and pemoline on cognitive functioning in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Single dose of methylphenidate improves cognitive performance in multiple sclerosis patients with impaired attention process

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Effects of l-amphetamine sulfate on cognitive function in multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

The effects of L-amphetamine sulfate on cognition in MS patients: results of a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Donepezil improved memory in multiple sclerosis in a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

A longitudinal study of cognition in primary progressive multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Benign multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

ApolipoproteinE epsilon 4 allele is not associated with disease course and severity in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

A phase III trial of intramuscular recombinant interferon beta as treatment for exacerbating-remitting multiple sclerosis: design and conduct of study and baseline characteristics of patients. Multiple Sclerosis Collaborative Research Group (MSCRG).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Cognitive impairment in multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing–remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Cognitive dysfunction in multiple sclerosis.: II. Impact on employment and social functioning

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Neocortical volume decrease in relapsing-remitting MS patients with mild cognitive impairment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Cognitive impairment in patients with multiple sclerosis using the Brief Repeatable Battery-Neuropsychology test

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

The Brief Repeatable Battery of Neuropsychological Tests for Multiple Sclerosis: a preliminary serial study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Depression in multiple sclerosis: review and theoretical proposal

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Subjective fatigue is not associated with cognitive impairment in multiple sclerosis: cross-sectional and longitudinal analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

APOE epsilon4 and cognitive dysfunction in multiple sclerosis: a review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

APOE and risk of cognitive impairment in multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

APOE epsilon4 is associated with impaired verbal learning in patients with MS

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Thalamic atrophy and cognition in multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Frontal cortex atrophy predicts cognitive impairment in multiple sclerosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Influence of education and occupation on the incidence of Alzheimer's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Treatment with oral 3,4 diaminopyridine improves leg strength in multiple sclerosis patients: results of a randomized, double-blind, placebo-controlled, crossover trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Effects of rivastigmine on memory and cognition in multiple sclerosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

The effects of 4-aminopyridine on cognitive function in patients with multiple sclerosis: a pilot study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.61

Clinical and psychometrical study of a patient with memory disturbances

31 March 2020

1 reference

12 December 2020

Effects of acute relapses on neuropsychological status in multiple sclerosis patients

1 reference

12 December 2020

Cortical lesions in multiple sclerosis: combined postmortem MR imaging and histopathology.

1 reference

12 December 2020

Intraventricular CSF pulsation artifact on fast fluid-attenuated inversion-recovery MR images: analysis of 100 consecutive normal studies

1 reference

12 December 2020

Effects of using same- versus alternate-form memory tests during short-interval repeated assessments in multiple sclerosis.

1 reference

12 December 2020

Correlating brain atrophy with cognitive dysfunction, mood disturbances, and personality disorder in multiple sclerosis

1 reference

12 December 2020

Multiple sclerosis: a preliminary study of selected variables affecting rehabilitation outcome.

1 reference

12 December 2020

Clinical, neurophysiological, and magnetic resonance imaging correlations in multiple sclerosis

1 reference

12 December 2020

The Symbol Digit Modalities Test - Oral version: Italian normative data

1 reference

12 December 2020

Regional lobar atrophy predicts memory impairment in multiple sclerosis.

1 reference

12 December 2020

Multicenter randomized clinical trial of donepezil for memory impairment in multiple sclerosis

1 reference

12 December 2020

Validity of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS).

1 reference

12 December 2020

Apolipoprotein E ε4-positive multiple sclerosis patients develop more gray-matter and whole-brain atrophy: a 15-year disease history model based on a 4-year longitudinal study

1 reference

12 December 2020

L-amphetamine improves memory in MS patients with objective memory impairment.

1 reference

12 December 2020

The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRNEUROL.2011.61

1 reference

PubMed ID

21556031

Dimensions Publication ID

29 July 2017

0 references

1 reference

PubMed ID

21556031